Welcome to our dedicated page for Raysearch Laboratories Ab news (Ticker: RSLBF), a resource for investors and traders seeking the latest updates and insights on Raysearch Laboratories Ab stock.
RaySearch Labs AB Ord (stock symbol: RSLBF) is a renowned medical technology company that develops advanced software solutions for enhanced cancer treatment. The company offers cutting-edge products like RayStation* treatment planning system, RayCare* oncology information system, RayIntelligence*, and RayCommand*. With over 1,000 clinics in 43 countries using their software, RaySearch remains a global leader in the industry. Founded in 2000 as a spin-off from the Karolinska Institute, RaySearch has continuously focused on innovation and technological advancement to improve patient outcomes.
RaySearch Laboratories has announced its upcoming Year-end report presentation for 2024, scheduled for February 21, 2025, at 10:00 am CET. The report will be released earlier the same day at 07:45 am CET and will be accessible on raysearchlabs.com along with presentation slides.
The presentation will be conducted via webcast, featuring Johan Löf, founder and CEO, and Nina Grönberg, CFO, who will discuss the company's development. The presentation will be held in English, followed by a Q&A session for attendees.
Interested parties, including analysts, investors, and media representatives, can access the presentation through the provided webcast link: RaySearch Q4, 2024.
RaySearch Laboratories is celebrating its tenth anniversary of innovation in proton therapy at the PTCOG 62 conference in Singapore, from June 10-15, 2024. The company will showcase advancements in RayStation, RayCare, and RayIntelligence systems.
Since delivering its first proton plan in 2014, RayStation has been adopted by 120 centers globally. RayStation introduces features like automated replanning, LET optimization, and FLASH planning. RayCare enhances oncology workflows, and RayIntelligence offers cloud-based analytics for better decision-making.
A user meeting and various presentations will be part of PTCOG 62, highlighting ongoing research and user testimonials.
RaySearch Laboratories has released its interim report for Q1 2024. The company showed strong financial performance with order intake reaching SEK 238.5 M, net sales of SEK 257.2 M, and an operating profit of SEK 45.8 M. Profit after tax was SEK 36.7 M, and earnings per share stood at SEK 1.07. Significant events included RayStation's implementation in over 1,000 radiotherapy centers and the acquisition of DrugLog. Post-reporting period highlights include a collaboration agreement with C-RAD and RayCare being certified for interoperability with Varian TrueBeam.
The Annual General Meeting 2021 of RaySearch Laboratories AB was held on May 26, 2021, via postal voting due to the pandemic. Key resolutions included the re-election of board members, approval of financial statements, and the adoption of remuneration guidelines for senior executives. Accumulated profits of SEK 202,699,000 will be balanced in new accounts. The meeting also confirmed Ernst & Young as the auditor and approved the board's remuneration report for 2020. Further information is available on raysearchlabs.com.
FAQ
What is the current stock price of Raysearch Laboratories Ab (RSLBF)?
What is the market cap of Raysearch Laboratories Ab (RSLBF)?
What does RaySearch Labs AB Ord specialize in?
What are some of the key products offered by RaySearch Labs AB Ord?
Where is RaySearch Labs AB Ord headquartered?
When was RaySearch Labs AB Ord founded?
What sets RaySearch Labs AB Ord apart from its competitors?
